FesariusTherapeutics receives NIH Commercial Readiness grant for DermiSphere™ dermal regeneration template in preparation for market release

Posted on by

BROOKLYN, N.Y., Aug. 16, 2023 /PRNewswire/ — FesariusTherapeutics, Inc., an emerging bioregenerative technology company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care markets, today announced they have been awarded an…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.